171 related articles for article (PubMed ID: 36820913)
1. A RUNX1/ETO-SKP2-CDKN1B axis regulates expression of telomerase in t (8;21) acute myeloid leukemia.
Moses EJ; Azlan A; Khor KZ; Mot YY; Mohamed S; Seeni A; Barneh F; Heidenreich O; Yusoff N
Cell Mol Life Sci; 2023 Feb; 80(3):70. PubMed ID: 36820913
[TBL] [Abstract][Full Text] [Related]
2. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
Ptasinska A; Assi SA; Mannari D; James SR; Williamson D; Dunne J; Hoogenkamp M; Wu M; Care M; McNeill H; Cauchy P; Cullen M; Tooze RM; Tenen DG; Young BD; Cockerill PN; Westhead DR; Heidenreich O; Bonifer C
Leukemia; 2012 Aug; 26(8):1829-41. PubMed ID: 22343733
[TBL] [Abstract][Full Text] [Related]
3. The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation.
Martinez-Soria N; McKenzie L; Draper J; Ptasinska A; Issa H; Potluri S; Blair HJ; Pickin A; Isa A; Chin PS; Tirtakusuma R; Coleman D; Nakjang S; Assi S; Forster V; Reza M; Law E; Berry P; Mueller D; Osborne C; Elder A; Bomken SN; Pal D; Allan JM; Veal GJ; Cockerill PN; Wichmann C; Vormoor J; Lacaud G; Bonifer C; Heidenreich O
Cancer Cell; 2018 Oct; 34(4):626-642.e8. PubMed ID: 30300583
[TBL] [Abstract][Full Text] [Related]
4. RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
Ptasinska A; Pickin A; Assi SA; Chin PS; Ames L; Avellino R; Gröschel S; Delwel R; Cockerill PN; Osborne CS; Bonifer C
Cell Rep; 2019 Sep; 28(12):3022-3031.e7. PubMed ID: 31533028
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.
Guo C; Li J; Steinauer N; Wong M; Wu B; Dickson A; Kalkum M; Zhang J
J Biol Chem; 2020 Mar; 295(13):4212-4223. PubMed ID: 32071087
[TBL] [Abstract][Full Text] [Related]
6. RUNX1/ETO regulates reactive oxygen species (ROS) levels in t(8,21) acute myeloid leukaemia via FLT3 and RAC1.
Azlan A; Khor KZ; Rajasegaran Y; Rosli AA; Said MSM; Yusoff NM; Moses EJ
Med Oncol; 2023 Jun; 40(7):208. PubMed ID: 37341821
[TBL] [Abstract][Full Text] [Related]
7. The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.
Bakshi R; Zaidi SK; Pande S; Hassan MQ; Young DW; Montecino M; Lian JB; van Wijnen AJ; Stein JL; Stein GS
J Cell Sci; 2008 Dec; 121(Pt 23):3981-90. PubMed ID: 19001502
[TBL] [Abstract][Full Text] [Related]
8. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
[TBL] [Abstract][Full Text] [Related]
9. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.
Gessner A; Thomas M; Castro PG; Büchler L; Scholz A; Brümmendorf TH; Soria NM; Vormoor J; Greil J; Heidenreich O
Leukemia; 2010 Oct; 24(10):1751-9. PubMed ID: 20686504
[TBL] [Abstract][Full Text] [Related]
10. Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.
Pulikkan JA; Madera D; Xue L; Bradley P; Landrette SF; Kuo YH; Abbas S; Zhu LJ; Valk P; Castilla LH
Blood; 2012 Jul; 120(4):868-79. PubMed ID: 22613795
[TBL] [Abstract][Full Text] [Related]
11. Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.
DeKelver RC; Lewin B; Lam K; Komeno Y; Yan M; Rundle C; Lo MC; Zhang DE
PLoS Genet; 2013; 9(10):e1003765. PubMed ID: 24130502
[TBL] [Abstract][Full Text] [Related]
12. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia.
Issa H; Swart LE; Rasouli M; Ashtiani M; Nakjang S; Jyotsana N; Schuschel K; Heuser M; Blair H; Heidenreich O
Leukemia; 2023 Apr; 37(4):820-834. PubMed ID: 36823395
[TBL] [Abstract][Full Text] [Related]
14. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.
Goyama S; Schibler J; Gasilina A; Shrestha M; Lin S; Link KA; Chen J; Whitman SP; Bloomfield CD; Nicolet D; Assi SA; Ptasinska A; Heidenreich O; Bonifer C; Kitamura T; Nassar NN; Mulloy JC
Leukemia; 2016 Mar; 30(3):728-39. PubMed ID: 26449661
[TBL] [Abstract][Full Text] [Related]
15. RUNX1 inhibits proliferation and induces apoptosis of t(8;21) leukemia cells
Liu S; Xing Y; Lu W; Li S; Tian Z; Xing H; Tang K; Xu Y; Rao Q; Wang M; Wang J
Haematologica; 2019 Aug; 104(8):1597-1607. PubMed ID: 30792202
[TBL] [Abstract][Full Text] [Related]
16. Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML.
Trinh BQ; Ummarino S; Zhang Y; Ebralidze AK; Bassal MA; Nguyen TM; Heller G; Coffey R; Tenen DE; van der Kouwe E; Fabiani E; Gurnari C; Wu CS; Angarica VE; Yang H; Chen S; Zhang H; Thurm AR; Marchi F; Levantini E; Staber PB; Zhang P; Voso MT; Pandolfi PP; Kobayashi SS; Chai L; Di Ruscio A; Tenen DG
Blood; 2021 Oct; 138(15):1331-1344. PubMed ID: 33971010
[TBL] [Abstract][Full Text] [Related]
17. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
18. The RUNX1-ETO fusion protein trans-activates c-KIT expression by recruiting histone acetyltransferase P300 on its promoter.
Chen G; Liu A; Xu Y; Gao L; Jiang M; Li Y; Lv N; Zhou L; Wang L; Yu L; Li Y
FEBS J; 2019 Mar; 286(5):901-912. PubMed ID: 30637949
[TBL] [Abstract][Full Text] [Related]
19. Biophysical and pharmacokinetic characterization of a small-molecule inhibitor of RUNX1/ETO tetramerization with anti-leukemic effects.
Gopalswamy M; Kroeger T; Bickel D; Frieg B; Akter S; Schott-Verdugo S; Viegas A; Pauly T; Mayer M; Przibilla J; Reiners J; Nagel-Steger L; Smits SHJ; Groth G; Etzkorn M; Gohlke H
Sci Rep; 2022 Aug; 12(1):14158. PubMed ID: 35986043
[TBL] [Abstract][Full Text] [Related]
20. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.
Dunne J; Gascoyne DM; Lister TA; Brady HJ; Heidenreich O; Young BD
Cancer Res; 2010 May; 70(10):3985-95. PubMed ID: 20460523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
